2018-07-10
CDNF – a biological protein – is Herantis’ lead program and a clinical stage asset; and xCDNF (a synthetic peptide version of CDNF) is Herantis’ follow-on program. Both CDNF and xCDNF, via their multimodal mechanism of action, have the potential to improve neuronal survival and stop the progression of Parkinson’s and other
The ongoing study aims to evaluate the safety and tolerability of CDNF delivered directly to the brain in 17 people with advanced Parkinson's. 2019-08-28 Herantis also announced today the next step for the CDNF program with the planning of a Phase 2 study with a longer treatment period that will assess the efficacy of CDNF in earlier-stage, well-characterized Parkinson’s patients. 2020-03-05 Supported by a strong preclinical proof-of-concept Herantis launched a first-in-human, randomized Phase 1-2 clinical study with CDNF in the treatment of Parkinson's disease (PD). The clinical study has received funding from the European Union's research and innovation program Horizon 2020 under the grant agreement number 732386. Subject to finalizing definitive agreements, Nanoform will in this partnership carry out, for compensation on standard commercial terms, two Proof of Concept studies on Herantis' CDNF and xCDNF Nanoform is committed to supporting Herantis in the development of these programs and has undertaken to invest, subject to certain customary conditions, 1,600,000 euros in a planned immediate directed share issue by Herantis. “We are delighted to support Herantis Pharma in their development programs in CDNF and latest generation xCDNF molecules.
Idag innehas särskilt fokus mot behandling av ett flertal sjukdomar som Parkinsons sjukdom, skleros samt bröstcancer. Bolaget innehar en produktportfölj som för närvarande befinner sig i diverse kliniska faser. 2020-02-25 · Source: Herantis It is cold this time of year in Helsinki, but there will be some warm smiles there today. A small biotech firm called Herantis Pharma has announced the topline results of their Phase 1/2 clinical trial exploring the safety and tolerability of a treatment called CDNF. Herantis announced today the topline results from the ongoing Phase 1-2 clinical trial examining Herantis’ proprietary neuroprotective factor and novel drug candidate, CDNF, in patients with Parkinson’s disease. 2019-08-28 · Herantis has patented CDNF internationally. Herantis has advanced CDNF into a Phase 1-2, randomized, placebo-controlled clinical study, that evaluates safety and initial efficacy of CDNF compared 2021-02-09 · Helsinki, Finland – Nanoform Finland Plc, an innovative nanoparticle medicine enabling company, and Herantis Pharma Plc, an innovative clinical stage biotech company, today announced that they have signed a Biologics Proof of Concept Agreement for formulation Proof of Concept projects (PoCs) aiming to enhance nasal drug delivery to the brain of Herantis’ CDNF therapies for Parkinson’s Herantis Pharma has published initial results from a phase 1/2 study of an experimental protective protein called CDNF which may hold potential to slow, stop or reverse Parkinson's.
Completing this Celles-ci comprennent la thérapie biologique CDNF qui agit sur les mécanismes protéostatiques de la maladie pour le traitement de la maladie de Parkinson et These include i.
Herantis Pharma är ett finskt forskningsbolag noterat i Helsingfors, med två mot Parkinsons sjukdom är ett naturligt protein som heter CDNF.
Herantis Pharma Published the Annual Report for the Financial Year 2020. Read more .
Supported by a strong preclinical proof-of-concept Herantis launched a first-in-human, randomized Phase 1-2 clinical study with CDNF in the treatment of Parkinson's disease (PD). The clinical study has received funding from the European Union's research and innovation program Horizon 2020 under the grant agreement number 732386.
Studien har fått EU stöd och sponsorn är Herantis Pharma (https://treater.eu; ClinicalTrials.
CDNF biological therapy that acts on the proteostatic mechanisms of disease for the treatment of Parkinson’s disease and other neurodegenerative diseases, and ii. Herantis Pharma Plc is an innovative drug development company looking to break the boundaries of standard therapeutic approaches. Our regenerative medicine drug candidates include i. CDNF biological therapy that acts on the proteostatic mechanisms of disease for the treatment of Parkinson’s disease and other neurodegenerative diseases, and ii. CDNF – a biological protein – is Herantis’ lead program and a clinical stage asset; and xCDNF (a synthetic peptide version of CDNF) is Herantis’ follow-on program. Both CDNF and xCDNF, via their multimodal mechanism of action, have the potential to improve neuronal survival and stop the progression of Parkinson’s and other
CDNF is patented internationally by Herantis. In preclinical studies it has definitively been shown to be safe and effective.
Essec
29 March 2021 at 9:00 PM EET. Herantis Pharma Plc (“Herantis or the Company”), an innovative clinical stage biotech company pioneering new disease modifying and regenerative therapies, today announced that the Board of Directors has decided to focus all company resources on Herantis’ CDNF and xCDNF assets and to commence seeking Herantis Pharma Announces an Oral Presentation and a Poster Presentation related to First-in-Man CDNF Clinical Trial at AD/PD™ Virtual Conference Read more Proposals of the Shareholders’ Nomination Committee to Herantis Pharma Plc’s Annual General Meeting 2021 Herantis Pharma has announced that its novel drug candidate, Cerebral Dopamine Neurotrophic Factor (CDNF) for the treatment of Parkinson’s disease (PD), has successfully achieved its primary endpoint of safety and tolerability in a 12 month Phase I-II study in patients with moderate disease.
followed by repeated and increased CDNF or placebo dosing for 6 months,
CDNF is a protein naturally present in humans. It was discovered by Professor Mart Saarma’s laboratory at the University of Helsinki and published in the leading scientific journal, Nature, in 2007. Based on this discovery, Herantis has secured worldwide patents for CDNF and launched a drug development program.
Hunddagis uddevalla kommun
CDNF is a protein naturally present in humans. It was discovered by Professor Mart Saarma’s laboratory at the University of Helsinki and published in the leading scientific journal, Nature, in 2007. Based on this discovery, Herantis has secured worldwide patents for CDNF and launched a drug development program.
Herantis is taking this natural ability and harnessing it as a treatment for neurodegenerative disease. CDNF – a biological protein – is Herantis' Nanoform and Herantis partner to look for opportunities to enhance BBB penetration of CDNF and xCDNF molecules CDNF-studieläkemedlet administreras in i hjärnan via katetrar. Mer information om studien fås från TreatER-studiens nätsida: https://treater.eu/sv/clinical-study/.
Eva erlandsson
Nanoform is committed to supporting Herantis in the development of these programs and has undertaken to invest, subject to certain customary conditions, 1,600,000 euros in a planned immediate directed share issue by Herantis. “We are delighted to support Herantis Pharma in their development programs in CDNF and latest generation xCDNF molecules.
CDNF biological therapy that acts on the proteostatic mechanisms of disease for the treatment of Parkinson's disease and other neurodegenerative diseases, and ii. Herantis Pharma Plc is an innovative drug development company looking to break the boundaries of standard therapeutic approaches. Our regenerative medicine drug candidates include i. CDNF biological therapy that acts on the proteostatic mechanisms of disease for the treatment of Parkinson’s disease and other neurodegenerative diseases, and ii. The intranasal administration route of CDNF is an important program for Herantis to maximize the chances of success for CDNF in brain disorders. We are excited to evaluate the Nanoform technology as part of this initiative; and we look forward to what this partnership will bring.